Biotech Phase I

Phase I.

Guiding clinical-phase decisions to create asset value.

We understand that early clinical development involves making decisions critical to the future success of your asset. Whether it’s selecting dosing options, understanding the implications for different modes of application or defining your clinical evidence needs to support Target Product Profile (TPP) and regulatory requirements, we have the specific knowledge and expertise to help.

Delivering personalized services with a dedicated team coordinated through a single strategic point of contact. Our science and commercial teams are backed by over 650 PhDs that guide the decisions that help you create and maximize value for your asset as you begin and progress through early-stage trials.

Explore Biotech

Key Phase I services.

Our services are highly personalized to you – we scale and flex as you need. These are some common services we deliver to companies with Phase I assets:

Opportunity assessment and prioritization including disease areas, assets and indications

 Future landscape assessment including clinical and high-level competitive environment

 Clinical evidence needs including TPP and regulatory requirements

Corporate communications including investor-, public- and media relations

Maximize tomorrow.

Maximizing your next value creation opportunity is within reach, start a conversation with one of our subject matter experts and access the expertise you need today.